US 6240394

I'll verify the patent details and check for any litigation/docket activity.

US Patent 6,240,394 B1 — Verification Summary

Note on scope: I searched for the exact identifier "6240394" and confirmed the record against Google Patents, EveryPatent, USPTO-report, and the Stanford NPE Litigation Database. No Court of Appeals for the Federal Circuit (CAFC) 2026 docket entries tied to this patent surfaced in my searches — see the caveat at the end.

Bibliographic Data

Assignee history is non-trivial: assigned to Catalina Marketing International, Inc. at filing; merged into Catalina Marketing Corporation (2006); assigned to Inventiv Health, Inc. (2013); and subsequently subject to a long chain of security interests (Morgan Stanley, Bank of America, Wilmington Trust, Citibank, Goldman Sachs, Credit Suisse, JPMorgan Chase). Google Patents lists the current assignee as Syneos Health US Inc. — that field is derived from reassignment records and should be treated as approximate rather than as legal confirmation of ownership.

Abstract (verbatim)

"A system for generating targeted advisory messages for pharmacy patients based on selected monitored data components of each transaction. When a pharmacy computer prints transaction data, the system monitors the data using printer data capture hardware interposed between the pharmacy computer and its printer. An additional processor compares selected components of the monitored transaction data with preselected combinations of the these components in a database. The database associates the preselected combinations of transaction data components with advisory message components retrieved from the database and used to build an advisory message for output to a printer, which may be the pharmacy computer or an additional printer. Targeting of the advisory messages is based on selected combinations of the identity of the drug being dispensed to the patient, the patient's age and gender, the new or renewal status of the prescription, and the identity of the party primarily responsible for payment to the pharmacy for the transaction."

Plain-Language Overview of the Independent Claims

Claim 1 — Method (the core "eavesdrop and target" method):
A four-step method: (1) capture a data record that a pharmacy computer sends to a pharmacy printer, where that record contains components describing a pharmacy transaction in which a product is dispensed to a patient; (2) compare selected components of that captured record against components in a database to figure out what an advisory message should say; (3) build the advisory message based on the comparison results; and (4) transmit the message to the pharmacy printer so it prints, keyed to the selected components of the captured record. In plain terms: watch the pharmacy's existing print stream, look up matching advice in a database, and print that advice at the pharmacy.

Claim 8 — Apparatus (the hardware counterpart):
A system for use in a pharmacy computer system that has a pharmacy processor and at least one printer, comprising: (a) a hardware interface coupled between the pharmacy processor and the printer(s) that captures the transaction data record sent to the printer; (b) a database holding components used to build an advisory message; and (c) an additional processor coupled to the database and the hardware interface that compares selected components of the captured record against the database, determines the message contents, and builds the message. Either the hardware interface or the additional processor transmits the message to the printer so it prints based on the captured components. In plain terms: a box sitting inline between the pharmacy computer and its printer, plus a second computer and database that generate and inject targeted printouts.

Dependent claims (all depend on claim 1 or claim 8 — none are independent):

• Claims 2–6 / 9–13 add targeting factors: patient age + drug identity; patient gender + drug identity; payer identity + drug identity; new-vs-refill status + drug identity; or drug identity plus at least one of those four factors.
• Claim 7 adds distributing a product sample with the advisory message.
• Claims 14–16 cover the hardware interface variants: 14 = parallel-to-serial conversion with parallel return path and printer-conflict mediation; 15 = serial tap with parallel advisory-message return and printer-side conflict mediation; 16 = two-printer configuration where the serial tap monitors the advisory printer.

The specification also discloses specific age bands used in the preferred embodiment (0–1, 2–4, 5–11, 12–18, 19–25, 26–35, 36–45, 46–60, over 60), a first-come-first-served printer-arbitration protocol with ~2–3 second timeouts, and a worked example involving Bactrim/Septra (sulfamethoxazole-trimethoprim) keyed to age, gender, refill status, and payer.

Litigation Posture

Both records I found concern Catalina Marketing Corporation (the eventual owner) as plaintiff:

1. Catalina Marketing Corporation v. LDM Group, LLC — Civil Action 4:09-cv-01114, E.D. Mo. (Missouri Eastern District Court). Source: https://npe.law.stanford.edu/patent/6240394 and Google Patents' Unified Patents litigation link.
2. Texas Eastern District Court case 2:07-cv-00477 — flagged as "Critical" in Google Patents' litigation data.

Google Patents additionally notes a first worldwide family litigation filing (Darts-ip family ID 25069796). The asserted patent is expired (12/12/2016), so these are historic disputes.

Uncertainty / Caveats

• CAFC 2026 dockets: My searches returned no 2026 Federal Circuit activity for US 6,240,394. A 2026 CAFC appeal would be unusual given the patent expired in 2016, but I could not query the CAFC docket system directly — only general web search was available. I therefore cannot state affirmatively that no 2026 CAFC filing exists; I can only report that none was found. Treat this as an unresolved item rather than a clean negative.
• USPTO records: I did not access PatentCenter/Patent Assignment Search directly; the bibliographic data above is corroborated across Google Patents, EveryPatent, USPTO.report, and Radaris inventor listings, which agree on number, title, inventors, dates, and assignee at issuance.
• Assignee currency: The "Syneos Health US Inc." current-assignee field is Google's automated attribution from the reassignment chain and is explicitly disclaimed by Google as potentially inaccurate.
• Do not conflate this patent with the related US 6,067,524 ("Method and system for automatically generating advisory information for pharmacy patients along with normally transmitted data," Byerly & Uecker, filed Jan. 7, 1999) or US 6,304,849 ("Method and system for printing a combination pharmaceutical label and directed newsletter," Uecker & Byerly, filed Feb. 23, 2000) — same corporate family and overlapping inventors, but distinct patents and distinct claims.

I'll research litigation involving US patent 6240394. Let me run several targeted searches.

Good leads. Let me drill into the specific case records referenced by the patent page and the Stanford NPE database.

Let me dig further into the outcome of that case and check for any other suits or PTAB proceedings.

Litigation involving U.S. Patent No. 6,240,394

Summary: Only one patent-infringement action is documented against this patent, and it generated two docket numbers as it moved from the Eastern District of Texas to the Eastern District of Missouri. I found no appeals (CAFC), no ITC investigations, and no PTAB proceedings (IPR/PGR/CBM) directed at the ’394 patent.

Case table

Details and sourcing

Case 1 — E.D. Tex. phase (2:07-cv-00477):

• The complaint was filed Nov. 1, 2007, by Catalina Marketing Corporation (a Delaware corporation, principal place of business St. Petersburg, FL) against LDM Group (a Missouri LLC, principal place of business St. Louis, MO). The court's memorandum opinion states the suit alleged infringement of "United States Patent No. 6,240,349." Note: I am reproducing that number literally as it appears in the retrieved opinion text; the patent at issue in this docket is the ’394 patent, so this appears to be a typographical/OCR variance in the opinion source rather than a different patent. (Justia opinion text)
• Judge Ward's order denied LDM's § 1406(a) motion to dismiss and § 1404(a) motion to transfer, and denied as moot LDM's motion to strike the Parish affidavit; the order is signed 9/9/08. Notably, the judge's opinion bears an E.D. Tex. caption and Judge Ward's signature, even though the Justia page is filed under the E.D. Mo. docket number.
• A venue-transfer report lists "Catalina Marketing Corporation v. LDM Group, LLC, 2-07-cv-00477 (TXED January 29, 2009, Order)" among Eastern District of Texas cases transferred out. (Docket Report blog)

Case 1 — E.D. Mo. phase (4:09-cv-01114):

• Plaintiffs are listed as Catalina Marketing Corporation and Catalina Health Resource, LLC; defendant LDM Group, LLC. Cause of action: 35 U.S.C. § 271 patent infringement. (dockets.justia.com E.D. Mo. IP browse; plainsite docket — status: Closed)
• The case was litigated through at least claim construction, invalidity, and non-infringement contentions; a defense expert (Dr. Val DiEullis, retained by Lewis, Rice & Fingersh for LDM) consulted on those issues. (expert CV; PTACTS exhibit)
• The Stanford NPE Litigation Database lists this patent with exactly this case (and its E.D. Tex. predecessor), classifying Catalina as a "Product company" / practicing entity rather than an NPE. (Stanford NPE DB — patent 6240394; case record)

Cross-check against the patent record

Google Patents' litigation data for US6240394B1 lists precisely these two proceedings — the Texas Eastern District Court case (2:07-cv-00477) and the Missouri Eastern District Court case (4:09-cv-01114) — plus a Darts-IP "first worldwide family litigation" link. No other jurisdiction is flagged. (US6240394B1 on Google Patents)

What I did not find

• No CAFC appeal of either docket number surfaced.
• No PTAB proceeding (IPR, PGR, or CBM) on the ’394 patent surfaced. The one PTAB-hosted document referencing the case is an expert's CV submitted in an unrelated petition.
• No ITC Section 337 investigation.
• No suits by successors-in-interest (e.g., ADHERIS, LLC or Syneos Health US Inc., the current assignee) on this patent surfaced.

Confidence and caveats

• The existence, parties, courts, and case numbers for Case 1 are well corroborated across the court opinion, docket aggregators, the Stanford NPE database, and the patent record itself.
• The precise filing date in E.D. Mo. (July 15, 2009) comes from docket aggregators, not PACER directly; the original E.D. Tex. complaint date (Nov. 1, 2007) comes from Judge Ward's opinion.
• The final disposition of 4:09-cv-01114 (e.g., settlement, voluntary dismissal, or consent judgment) is not confirmed — aggregators show only "Closed"/a termination date. I did not verify this against PACER, so I state it as unconfirmed rather than asserting an outcome.
• I was unable to reach the Unified Patents litigation portal or PACER directly within this session; all findings are from secondary/aggregator sources, and the Google Patents page itself cites Unified Patents and Darts-IP as the source for the two cases above.

Proceedings overview

Zero AIA trial proceedings. The structured "PTAB proceedings on file" block — the canonical USPTO Open Data Portal list supplied with this prompt — returns no AIA trials (no IPR, PGR, or CBM) involving US 6,240,394, and my independent web searches did not surface any petition, institution decision, FWD, or PTAB appeal that the ODP block might have missed. Breakdown by status is therefore trivially: 0 active / 0 claims invalidated / 0 claims sustained / 0 settled / 0 institution denied.

Bottom line for a defendant: this is not the "hardened after surviving IPRs" posture, and it is not the "claims 1–5 are canceled" posture either. It is the third, less-discussed posture: an untested patent whose entire claim set (claims 1–16) stands exactly as issued on 2001-05-29, with no PTAB estoppel of any kind on either side. Every claim — including independent method claim 1 and independent apparatus claim 8 — is live ink in the record. But the patent expired 2016-12-12, which means the AIA window is shut as a practical matter (see caveats), so the practical defense is a district-court §§ 102/103/112 and § 101 fight, not a PTAB fight.

No proceedings to report

There is no IPR20XX-XXXXX, PGR20XX-XXXXX, or CBM20XX-XXXXX number to give you for this patent. I will not generate placeholder numbers. The absence is the finding.

Strategic summary

Claim status: 1–16 all UNTESTED and therefore all literally in force (as of last day of enforceability). Because nothing was ever instituted, there is no claim-cancellation certificate, no substitute claim, no adverse judgment, and no statutory disclaimer on record for 6,240,394. Independent claim 1 (capture → compare → build → transmit to the pharmacy printer) and independent claim 8 (hardware interface + database + additional processor, with the transmitting means in either the interface or the processor) are intact. Dependent claims 2–6 and 9–13 (age/gender/payer/new-vs-refill targeting), claim 7 (product sample distribution — note this is a method claim step, which is an unusual and potentially vulnerable drafting choice), and claims 14–16 (parallel-to-serial capture; serial tap; two-printer serial tap) were never construed by the Board.

Estoppel landscape — § 315(e)(2) is a non-issue. For § 315(e)(2) estoppel to attach, you need an IPR that "results in a final written decision under section 318(a)." That never happened here. Consequently no party and no privy is barred from raising any § 102 or § 103 ground, on any reference, printed publication or patent, before the district court. There is also no § 325(e) PGR estoppel and no § 315(e)(1) Office-side estoppel. The flip side: Catalina/Syneos also never had to defend anything, so it obtained no Board-side claim-construction or validity findings it could now use defensively in litigation. Symmetrically clean slate.

Pattern signals. No serial-petition pattern (zero petitions), no joinder contests, no Director Review orders, no Federal Circuit appeal from a Board decision, and no defensive aggregator in the chain — the Stanford NPE Litigation Database record for patent 6240394 (https://npe.law.stanford.edu/patent/6240394) lists Catalina Marketing Corporation as the asserter in the E.D. Mo. action, i.e. the patent was asserted by its operating-company owner, not by a Unified Patents-style petitioner-side entity. Notably, Unified Patents appears in the Google Patents record only as litigation-data source, not as a petitioner. The two historic suits — 2:07-cv-00477 (E.D. Tex., flagged "Critical" by Google Patents) and 4:09-cv-01114 (E.D. Mo., Catalina Marketing Corp. v. LDM Group, LLC) — were both resolved without any PTAB challenge to this patent, which is itself notable given that LDM Group (St. Louis) later became an assignee of Uecker/Christenson continuation-family applications, i.e. the parties were institutionally familiar with the family.

Why the PTAB door is effectively closed now (context, not a finding about this patent).

1. Term. The patent's anticipated expiration was 1996-12-12 + 20 years = 2016-12-12, with the trailing § 286 six-year damages recovery window running to 2022-12-12. A petition filed today would be an expensive way to invalidate a claim set with no forward-looking damages exposure.
2. CBM is gone. CBM review was available only to patents with a claim to a "financial product or service" / "technological invention" and, more importantly, no new CBM petition could be filed after 2020-09-16 under AIA § 18(a)(3)/Sunset. Claims 1–16 (G06Q 30/02 marketing-targeting class) would have been plausible CBM candidates in 2013–2019 — note the presence of Catalina Mktg. Int'l v. Coolsavings.com, 289 F.3d 801 (Fed. Cir. 2002) in Catalina's own litigation history, showing the company had been on the § 101/§ 112 preamble-shifting end of eligibility fights — but that window is closed.
3. The 2025–26 "settled expectations" practice. Secondary sources report that on 2025-06-18 the USPTO announced a practice of denying IPR/PGR institution for patents that issued more than six years earlier, invoking the owner's "settled expectations," and that roughly 201 petitions were denied on that basis without merits consideration, with subsequent summary denials; this is described in an amicus brief filed 2026-09-16 in Kahoot (https://www.siia.net/wp-content/uploads/2026/09/2026.09.16-Kahoot-amicus-brief-FILED.pdf), and petition-side commentary appears in the Tessell amicus brief (https://fedcircuitblog.com/wp-content/uploads/2026/03/26-117_Tessell_Teodor-Holmberg-Amicus-Brief.pdf). I flag this as secondary-source context, not a verified USPTO rule text, and it is under active APA challenge — but the direction is unambiguous: a 1996-priority patent would fare badly at the institution threshold today. Treat the Kahoot/USPTO-rule items as items to verify against the Federal Register and the PTAB rules before relying on them.

Recommended next steps

1. If you are a defendant: do not budget for a PTAB strategy. There is no FWD to link to and no cancellation certificate to quote — I want to be explicit that I am not asserting claims are dead, because they are not. Your invalidity case lives in the district court under §§ 102/103/112 and § 101, with the full pre-AIA § 282 burden on you (clear and convincing), and with no § 315(e)(2) limit on which references you may use. That is a rare luxury: you can run every ground — including prior public use/sale and system-prior-art evidence about the 1995–96 point-of-sale coupon systems (Medi-Link, ActMedia, Health Resource, Medi-Span/Target Rx) that appear in the 48 non-patent citations on the face of this patent — without the printed-publication-only restriction of § 311(b).
2. Attack the specification's admissions, not a hypothetical Board record. The patent's own background describes prior systems that generated advisory messages "based principally on the identification of a prescription drug being purchased" and states that such systems "are satisfactory for some purposes." Combined with the file's dense NPL (all dated 1989–1996 and mostly describing pharmacy coupon/messaging rollouts), the obvious § 103 theory is that claim 1's four-step eavesdrop-compare-build-print method and claim 8's inline-tap-plus-second-processor apparatus were a predictable combination of known POS intercept hardware and known NDC-triggered messaging. The applicant's own "Disclosure by Applicants, by Baxter H. Byerly, dated Jul. 15, 1999" (listed in the file) is a document worth pulling from the patent's public file wrapper.
3. Watch § 101 for claim 7 and the "means for transmitting" language in claim 8. Claim 7 recites distributing a product sample — a physical, human-executed step appended to a software method, which invites an Alice step-two "insignificant extra-solution activity" attack. Claim 8's "means for transmitting" is a § 112(f) limitation whose scope depends entirely on the structures disclosed at Figs. 1, 4, 5 (printer conflict mediation logic 38, parallel-to-serial conversion circuitry 37) and the corresponding algorithms; narrow construction there is a non-infringement lever, not an invalidity lever.
4. Verify the negative before relying on it. Run the following and document the null result in your file:
   • PTAB public docket search for the patent number: https://ptacts.uspto.gov/ptabweb/#/search/patents (search 6240394 and 6,240,394)
   • PTAB API: https://developer.uspto.gov/ptab-api/ — query proceedings and documents by patent number
   • Reexamination / supplemental examination check in Patent Public Search (reexam certificates appear as RE-suffix documents on the patent's "Certificate of Correction"/"Reexamination Certificate" tab); my searches returned no reexamination certificate, but I could not query Patent Public Search directly
   • CourtListener full-text: https://www.courtlistener.com/?q=%226240394%22 — for any Federal Circuit or district opinion citing the number
5. Distinguish this case from its siblings before you write anything. The related patents US 6,067,524 (Byerly & Uecker, filed 1999-01-07, "along with normally transmitted data") and US 6,304,849 (Uecker & Byerly, filed 2000-02-23, combined label/newsletter) are separate patents with separate claim sets; a null PTAB result for 6,240,394 says nothing about them, and a clearance or invalidity opinion covering one does not cover the others.

Caveats

• I found no PTAB activity; I cannot prove a universal negative. The ODP block is canonical and returned zero rows; my web searches (queries on the patent number plus "IPR," "CBM," "PTAB," and petitioner/owner names) also returned zero. But I could not query PTAB E2E, the PTAB API, or Patent Public Search directly — only general web search. Proceeding with a documented manual E2E/API check (step 4) is the only way to close this out defensibly.
• Do not infer from litigation silence that the claims are weak. Catalina Marketing Corp. v. LDM Group, LLC (4:09-cv-01114, E.D. Mo.) and E.D. Tex. 2:07-cv-00477 produced no PTAB filing against this patent, but I was unable to retrieve the disposition of either case (my query on the E.D. Mo. outcome was cut off). Whether those cases settled, were dismissed, or went to judgment is unresolved and could materially change the defensive picture — a litigated judgment of invalidity or non-infringement would be far more useful to you than the absence of an IPR. Chase the dockets (PACER for 4:09-cv-01114 and 2:07-cv-00477, and the Stanford database record above) before you build a strategy on the null PTAB result.
• The "settled expectations" / Kahoot material is secondary-source. I have not verified the 2025-06-18 announcement or the 201-petition figure against the Federal Register or the USPTO's own rules page, and the underlying APA challenge is pending. Cite it as context only.
• Assignee naming is unsettled. Google Patents lists Syneos Health US Inc. as current assignee by automated derivation from the reassignment chain (Catalina → Inventiv Health → the various security-interest holders). Confirm the live owner and the correct entity to name before serving or answering anything.

I'll research the USPTO assignment records and cross-reference sources for this patent.

Good — I found reel/frame data for a sibling patent. Let me dig deeper into the actual assignment records for 6240394.

Ownership & Assignment Analysis — US 6,240,394 B1

Data-quality note up front: I was unable to reach the USPTO Assignment Center / Patent Assignment Search interface directly (it is a database query interface, not a crawler-indexed document set), and no mirror surfaced the reel/frame or correspondent fields for this patent's own records. What I can verify is the full sequence of recorded legal events (dates, conveyance types, assignors, assignees), which is corroborated across Google Patents' legal-events table, the Stanford NPE Litigation Database, and a sibling family patent (US 8,531,714) that shares the identical corporate chain. I have not retrieved reel/frame numbers or correspondent names for US 6,240,394 itself, and I will not fabricate them. Where I can point to a specific reel/frame, I say so and identify exactly which patent it belongs to.

Inventors

All three are recorded as assignors to Catalina Marketing International, Inc. on an "Assignment of Assignors Interest" executed and recorded 1996-12-12, the same day the application was filed (see timeline). That is a routine employee-invention assignment, not a departure signal.

• Geographic spread: two inventors in the St. Louis metro area (Chesterfield / St. Genevieve, MO) and one in central Florida (Clermont). This is consistent with a company with distributed staff rather than a single lab; I could not determine which physical site hosted the work.
• Byerly is a repeat inventor on the sibling family patents US 6,067,524 and US 6,304,849 (both same corporate family). He also filed a five-page "Disclosure by Applicants" dated 1999-07-15 during prosecution of this patent (listed among the non-patent citations).
• Could-not-verify: I found no evidence of whether any inventor left Catalina within 12 months of filing, so I cannot call the "all-inventors-depart" pattern either way. Treat as unclear / no data.

Prosecution attorney of record at issuance (from EveryPatent, not an assignment correspondent): Jeffrey N. Giunta and John J. Halak. Primary Examiner: Eric W. Stamber. These are the prosecuting agents, which is a different field from the Assignment-Center "correspondent of record" the task asks about.

Original assignee

Catalina Marketing International, Inc., St. Petersburg, FL (later merged into Catalina Marketing Corporation).

• Primary line of business: point-of-sale consumer marketing — the company that popularized checkout-printed targeted coupons. The claims here sit inside its pharmacy/health vertical (Catalina Health Resource), which delivered pharmacist-distributed advisory and adherence material keyed to the dispensing transaction.
• Did it ship a product embodying the claims? Yes, on the evidence available. The spec describes a fielded architecture (parallel/serial taps, print-stream arbitration, age/gender/payer/new-refill targeting), and Catalina is categorized as a product company by the Stanford NPE Litigation Database (asserter category "8 Product company"). This is the single most important fact for the verdict below.
• Current status: Catalina divested this asset before its own later troubles — it sold Catalina Health to inVentiv Health in October 2013 (announced 2013-10-31; recorded here as the 2013-11-26 assignment). Catalina Marketing itself later underwent financial restructuring/bankruptcy in 2017, but that post-dates the divestiture and did not put this patent into a bankruptcy estate. Hmm — I should flag this last item as moderate confidence, not verified in SEC filings during this session.

Assignment timeline

Caveat on this section: dates, conveyance types, and party names below are derived from the Google Patents legal-events record (itself sourced from USPTO assignment data) and are reliable. Reel/frame and correspondent fields were not retrievable for this patent, so they are marked [not retrieved] rather than invented. The chain runs well over a decade and mixes true Assignment conveyances with Security Agreement / Release financing instruments — do not read the security filings as ownership transfers.

• 1996-12-12 (executed = recorded 1996-12-12) — Reel [not retrieved]

  • Conveyance: Assignment of Assignors Interest
  • Assignor: Baxter Hayes Byerly Jr.; Robert Anthony Uecker; Michael James Ward
  • Assignee: Catalina Marketing International, Inc.
  • Correspondent: [not retrieved]
  • Context: Routine employee invention assignment at filing.

• 2006-06-27 — Reel [not retrieved]

  • Conveyance: Merger
  • Assignor: Catalina Marketing International, Inc.
  • Assignee: Catalina Marketing Corporation
  • Correspondent: [not retrieved]
  • Context: Internal corporate reorganization; no change in beneficial ownership.

• 2007-10-15 — Reel [not retrieved]

  • Conveyance: Security Agreement
  • Assignor: Catalina Health Resource LLC, Catalina Marketing Procurement LLC, Catalina Marketing Worldwide LLC, Catalina-Pacific Media LLC, Checkout Acquisition Corp., Checkout Holding Corp., CMJ Investments LLC
  • Assignee: Morgan Stanley & Co. Incorporated
  • Correspondent: [not retrieved]
  • Context: Securitization / collateral — not an ownership transfer.

• 2013-10-24 — Reel [not retrieved]

  • Conveyance: Security Agreement
  • Assignor: Catalina Marketing Corporation and affiliated LLCs
  • Assignee: Bank of America, N.A.
  • Correspondent: [not retrieved]
  • Context: Securitization — new lender collateral package.

• 2013-10-24 — Reel [not retrieved]

  • Conveyance: Release by Secured Party
  • Assignor: Morgan Stanley & Co. LLC (fka Morgan Stanley & Co. Incorporated)
  • Assignee: Catalina Health Resource LLC and affiliated Catalina LLCs
  • Correspondent: [not retrieved]
  • Context: Discharge of the 2007 Morgan Stanley security interest.

• 2013-11-26 — Reel [not retrieved]

  • Conveyance: Assignment of Assignors Interest
  • Assignor: Catalina Marketing Corporation
  • Assignee: inVentiv Health, Inc.
  • Correspondent: [not retrieved]
  • Context: True acquisition / divestiture — the Catalina Health business (and this patent) sold to inVentiv Health. A real change of ownership.

• 2013-12-19 — Reel [not retrieved]

  • Conveyance: Release by Secured Party
  • Assignor: Bank of America, N.A.
  • Assignee: Catalina Marketing Corporation and affiliated LLCs
  • Correspondent: [not retrieved]
  • Context: Discharge of the 2013 Bank of America security interest.

• 2014-08-26 — Reel [not retrieved] (two duplicate postings)

  • Conveyance: Patent Security Agreement
  • Assignor: inVentiv Health, Inc.
  • Assignee: Wilmington Trust, National Association, as Collateral Agent
  • Correspondent: [not retrieved]
  • Context: Securitization at the new owner.

• 2014-11-13 — Reel [not retrieved]

  • Conveyance: Security Interest
  • Assignor: inVentiv Health, Inc. → Assignee: Citibank, N.A.
  • Context: Securitization.

• 2014-12-10 — Reel [not retrieved]

  • Conveyance: Security Interest
  • Assignor: inVentiv Health, Inc. → Assignee: Citibank, N.A., as Administrative Agent
  • Context: Securitization.

• 2016-11-14 — Reel [not retrieved]

  • Conveyance: ABL Lien Intellectual Property Security Agreement
  • Assignor: Addison Whitney LLC; Adheris, LLC; BioSector 2 LLC; Blue Diesel LLC; Cadent Medical Communications LLC; Chamberlain Communications Group LLC; Chandler Chicco Agency LLC; Gerbig Snell/Weisheimer Advertising LLC; inVentiv entities; Palio + Ignite LLC; Pharmaceutical Institute LLC; The Selva Group LLC
  • Assignee: Bank of America, N.A., as Collateral Agent
  • Context: Portfolio-level securitization across the inVentiv group.

• 2016-11-14 — Reel [not retrieved]

  • Conveyance: First Lien Intellectual Property Security Agreement
  • Assignor: same inVentiv group entities as above → Assignee: Goldman Sachs Bank USA, as Collateral Agent
  • Context: Portfolio-level securitization (first lien).

• 2016-11-17 — Reel [not retrieved] (multiple postings)

  • Conveyance: Release by Secured Party
  • Assignor: Citibank, N.A. / Citibank, N.A. as Administrative Agent; and Wilmington Trust, National Association as Collateral Agent
  • Assignee: Adheris, LLC and inVentiv Health, Inc.
  • Context: Discharge of the 2014 Wilmington Trust and Citibank liens.

• 2016-12-12 — Anticipated expiration (patent term ends; not an assignment).

• 2017-09-01 — Reel [not retrieved]

  • Conveyance: Security Interest
  • Assignor: inVentiv group entities (incl. Adheris, LLC; INC Research, LLC; Addison Whitney, LLC)
  • Assignee: Credit Suisse AG, Cayman Islands Branch
  • Context: Refinancing securitization.

• 2017-09-05 — Reel [not retrieved] (two postings)

  • Conveyance: Release by Secured Party
  • Assignor: Goldman Sachs Bank USA (as agent) and Bank of America, N.A. (as agent)
  • Assignee: inVentiv group entities
  • Context: Discharge of the 2016 Goldman Sachs and Bank of America liens.

• 2019-03-26 — Reel [not retrieved]

  • Conveyance: Assignment of Security Interest in Intellectual Property Rights
  • Assignor: Credit Suisse AG, Cayman Islands Branch, as Collateral Agent
  • Assignee: JPMorgan Chase Bank, N.A., as Successor Collateral Agent
  • Context: Lender-side substitution of collateral agent — still a lien, not ownership.

Reel/frame cross-reference that I can anchor (sibling patent, not this one): the identical corporate chain appears on US 8,531,714 with these recorded reel/frames — 040360/0674, 040360/0695, 040360/0702 (2016-11 security interests), 043470/0878 and 043491/0141, 043491/0191 (2017 Credit Suisse / Goldman Sachs / BofA), 048618/0626 (inVentiv → Syneos change of name), 048702/0161 (2019 JPMorgan), 048886/0294 (corrective change of name), 054460/0153, 054450/0458, 056400/0117 (2020 Syneos/Adheris). These reels belong to US 8,531,714, not US 6,240,394, and I am citing them only to show the family-level recording pattern — I cannot confirm 6,240,394 sits on those same reels.

Correspondent across the chain: [not retrieved] for every entry. This is exactly the field that would let me test the "repeat-player lawyer" pattern, and it is unavailable in my sources. That absence is a material limitation on the NPE analysis below.

Timeline diagram

timeline
    title Ownership of US 6240394
    1996 : Inventors assign to Catalina Marketing International
    2001 : Patent issued
    2006 : Merger into Catalina Marketing Corporation
    2007 : Morgan Stanley security agreement
    2009 : Catalina sues LDM Group in E D Mo
    2013 : Lien released and new BofA lien
         : Catalina Health divested to inVentiv Health
    2014 : Wilmington Trust and Citibank security interests
    2016 : Goldman Sachs and BofA security interests
         : Patent expires
    2017 : Credit Suisse security interest
    2019 : JPMorgan Chase named successor collateral agent

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT. The only true ownership transfers are Catalina Marketing International → Catalina Marketing Corporation (merger, 2006) and Catalina Marketing Corporation → inVentiv Health, Inc. (asset/stock acquisition, 2013-11-26). No "IP / Patents / Licensing / Holdings / Ventures" entity appears anywhere in the chain. Adheris, LLC — the inVentiv subsidiary that recurs as a secured party in the 2016–2021 filings — is an operating medication-adherence company (NM foreign LLC #4453155, registered agent United Agent Group, still Active), not a single-purpose assertion vehicle.

2. Known asserter in the chain — NOT PRESENT. None of Catalina, inVentiv Health, Syneos Health, or Adheris matches the Acacia / Marathon / IV / IPNav / Wi-LAN / Conversant / Vringo / Pendrell / Round Rock / MPHJ lists. To the contrary, the Stanford NPE Litigation Database classifies the plaintiff in the only asserted case as a "Product company," not an NPE.

3. Repeat correspondent across the chain — UNCLEAR / NO DATA. I could not retrieve the correspondent of record for any 6,240,394 entry (see caveat above). No recurrence finding is possible. Explicitly not a finding either way.

4. Cascading transfers — NOT PRESENT. The chain spans 1996 → 2019 (23 years). The only <24-month clusters are lender-side security-interest roll-ups (2014 Wilmington/Citibank; 2016 Goldman/BofA), which are financings, not shell-to-shell asset shuffles. No shared-agent-address single-purpose LLC sequence.

5. Pre-litigation transfer — NOT PRESENT. The first asserted case, Catalina Marketing Corporation v. LDM Group, LLC (4:09-cv-01114, E.D. Mo.), was filed in 2009 — almost four years before the 2013-11-26 divestiture to inVentiv. At the time of suit the patent was owned by the operating company Catalina. There is no 6-month pre-suit assignment. (A second historic case, E.D. Tex. 2:07-cv-00477, predates the divestiture too.)

6. Bankruptcy fire-sale — NOT PRESENT for this patent. The patent left Catalina in 2013; Catalina Marketing's own financial restructuring came later (2017, moderate confidence) and therefore did not convey this patent. The 2014–2017 instruments here are consensual secured financings, not Article 9 / Chapter 11 dispositions.

7. Privateering — NOT PRESENT. No evidence that Catalina (or inVentiv/Syneos) transferred the patent to an NPE to assert against competitors. The single documented enforcement was by the operating owner itself.

8. Defensive aggregator — NOT PRESENT. The chain does not terminate at RPX, AST, LOT, Unified, or OIN. It terminates in the operating life-sciences services group (inVentiv → Syneos Health US, Inc.), with a 2019 lender-agent substitution to JPMorgan Chase that is a lien, not a neutralization.

Verdict

Operating-company assertion.

Justification: the two ownership-changing links in the record — the 2006-06-27 merger into Catalina Marketing Corporation and the 2013-11-26 acquisition by inVentiv Health, Inc. — are ordinary corporate transactions between operating companies, and the intervening filings are secured-financing instruments (Morgan Stanley, Bank of America, Wilmington Trust, Citibank, Goldman Sachs, Credit Suisse, JPMorgan Chase). The only documented enforcement, Catalina Marketing Corp. v. LDM Group, LLC, 4:09-cv-01114 (E.D. Mo.), was brought by the then-owner Catalina four years before it divested the asset, and the Stanford NPE Litigation Database tags that plaintiff as a "Product company." With no shell entity, no list-matched asserter, no pre-suit assignment, and no defensive-aggregator terminus, none of the NPE signals fire.

Verification links:

• USPTO Assignment Center search: https://assignment.uspto.gov/patent/index.html (query patent number 6240394 to pull the reel/frame and correspondent fields I could not reach)
• Stanford NPE Litigation Database: https://npe.law.stanford.edu/patent/6240394
• Google Patents (legal events): https://patents.google.com/patent/US6240394/en

The one thing to finish the job: pull the correspondent of record for each reel entry in Assignment Center. If a single attorney/firm recurs across the 2013 divestiture and the 2014–2017 lien filings, that is worth noting — but on the evidence in hand it would speak to lender-side collateral counsel, not to an NPE pattern.

I'll verify the USPTO record for 6240394 and pull details on the cited prior art.

Let me pull details on the remaining cited references.

Prior-Art Analysis — US 6,240,394 B1

1. USPTO record check (exact number: 6240394)

I confirmed the record only for 6,240,394 — no substitute or near-number was used.

Corroborating public records: Google Patents (https://patents.google.com/patent/[US6240394B1](/patent/US6240394B1)/en), USPTO.report (https://uspto.report/patent/grant/6240394), EveryPatent (http://www.everypatent.com/comp/pat6240394.html). These agree with the authoritative full text supplied.

Cross-reference note (no contradiction found): The earlier-generated section reported the same bibliographic data. My searches additionally corroborate the related-family distinction it drew — EP 1,141,874 A1 ("Method and system for automatically generating advisory information for pharmacy patients along with normally transmitted data"), applicants Byerly/Uecker, Catalina Marketing International, priority US 1999-0226209 (Jan. 7, 1999), PCT filed Feb. 3, 1999 — i.e., the US 6,067,524 family, distinct from the '394 patent (https://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=1141874).

2. Legal framework applied

The '394 patent has a December 12, 1996 priority/filing date, so pre-AIA 35 U.S.C. § 102 governs. A printed publication or patent qualifies under:

• § 102(a)/(b) — issued or published more than one year before Dec. 12, 1996, i.e., on or before Dec. 12, 1995; or
• § 102(e) — a U.S. patent "granted on an application for patent by another filed in the United States before the invention by the applicant." This matters here because many of the cited references issued after the '394 filing date but were filed earlier, so they can only be § 102(e) art.

This distinction is decisive and is flagged per reference below.

Threshold observation on the independent claims. Neither independent claim is anticipated by any cited reference, considered alone, because both require as a core element the capture of a data record "transmitted to a pharmacy printer from a pharmacy computer" (claim 1) / a "hardware interface coupled between said pharmacy processor and said at least one printer" (claim 8) — i.e., passive interception of the pharmacy's existing print stream. None of the 22–24 cited references discloses print-stream tapping. That element is the apparent point of novelty. Accordingly, the citations below are mapped to the individual claim limitations they actually touch; they are principally § 103 (obviousness) material, not § 102 anticipatory art against claims 1 or 8.

3. Patent citations, with dates and § 102 assessment

All dates are stated literally as they appear in the '394 record's citation tables (filing date → publication/grant date).

A. Point-of-sale coupon / targeted-incentive art (closest on "targeted, auto-generated printed message")

B. Pharmacy / drug-dispensing and patient-counseling art (closest on subject matter)

C. Consumer-data / authorization / payment art (peripheral)

4. Non-patent citations (48 items)

These are IDS-style references, not § 102 patents. They cluster into three groups and are worth noting because several are closer in subject matter than the patents:

• Pharmacy coupon / point-of-care programs: "Coupon Vehicles Set for Pharmacies" (Information Technology, Jan. 15, 1996); "Medi-Link Offers Point-Of-Care Coupon Promotions" (Dec. 1, 1995); "Medi-Span Enters Coupon Business With Target Rx" (May 1996); Robin Foote (Medi-Link President), "Medi-Link Coupon System Rolls-out at Wakefern, Snyder, May's, and Pharmhouse" (Apr. 11, 1996); "Drug Emporium adopts Rx system" (Chain Drug Review, Sep. 25, 1995); David Vaczek, "Kroger, Wakefern Testing Pharmacy Coupon Systems" (Pharmacy Retailing, Apr. 1995); Christina Veiders, "Retailers expanding health information/coupon systems (Health Resource and Medi-Link)" (Supermarket News, Oct. 9, 1995); Michael Wilke, "Actmedia Tries Coupons in Pharmacies" (Advertising Age, May 6, 1996).
• Pharmacy practice / IT: "Software Supplement Your Pharmacy Practice" (Computer Talk, May/Jun. 1996); Michael Slezak, "Programming pharmacy's future" (American Druggist, Oct. 1, 1995); Michael F. Conlan, "In-Your-Face Pharmacy" (Drug Topics, Jul. 8, 1996); CounseLabels, Liberty Bell Pharmacy (Jan. 11, 1996).
• Applicant disclosure: "Disclosure by Applicants, by Baxter H. Byerly, dated Jul. 15, 1999 and consisting of 5 pages." Under § 102(b)/Rule 56 practice this is the applicants' own late IDS submission; it is not itself prior art, but as an admission/disclosure it can bear on equitable-conduct and on what the applicants considered material.

5. Bottom line — ranking and the § 102 verdict

Most relevant prior art, in order:

1. US 4,847,764 (Meditrol) — only cited reference squarely in the pharmacy-dispensing + printer + drug-interaction-warning environment that claim 8 presupposes. § 102(b) art. Does not anticipate claims 1 or 8 (no print-stream capture, no age/gender/payer advisory targeting).
2. US 5,299,121 (Medscreen) — only cited reference that expressly keys drug information to patient age and gender. § 102(b) art. Best § 102 candidate for the added limitations of claims 2/9, 3/10, and (via its "male, over 40" rules and knowledgebase) arguably claims 6/13; but it fails every claim because it collects data by directly prompting the patient rather than capturing a pharmacy printer record, and because all dependent claims incorporate claim 1/8's capturing step.
3. US 4,723,212 + US 4,910,672 (Catalina) and US 5,832,457 (Catalina) — automatic, database-triggered generation of a targeted printed item at POS. § 102(b) for '212/'672; § 102(e) only for '457. Combined, they come closest to claim 1's compare → build → print sequence, but they generate coupons, not patient advisory messages, and do not capture a pharmacy print stream.
4. US 5,774,868 (IBM) and US 5,353,218 (Ad Response) — automatic promotion selection; § 102(e) and § 102(b) respectively. Relevant to claim 1's database-comparison step only.
5. US 5,597,995 (Automated Prescription Systems) and US 5,758,095 (Albaum) — pharmacy-transaction data environment; § 102(e) only (both issued after the '394 filing).

No reference, alone or in the record as cited, anticipates independent claim 1 or independent claim 8 of US 6,240,394, because none discloses the capture of the data record transmitted to the pharmacy printer / the hardware interface coupled between pharmacy processor and printer. The citations function as § 103 art for the individual downstream limitations (database lookup, message build, print, age/gender/payer/refill targeting), and several would be combinable with a POS-print-tap teaching.

6. Caveats and open items (stated explicitly)

• The governing legal question here is obviousness, not anticipation. I have mapped each reference to the claim limitations it actually touches, but I do not represent that any citation meets § 102 as to any claim; the record shows no such reference.
• § 102(e) dates are the reference filing dates as printed in the '394 citation tables, which I have reported literally. I did not independently re-verify every underlying application filing date at PatentCenter/Global Dossier; where a reference is a continuation (the Credit Verification '196/'812/'723/'114/'469 group, all listed at 1989‑05‑01), the effective § 102(e) date depends on the earliest U.S. filing in that chain, which I have not confirmed beyond the printed date.
• Common ownership. US 4,723,212, US 4,910,672 and US 5,832,457 are Catalina-family patents, i.e., the assignee's own art; this bears on (pre-AIA) § 103(c) disqualification and on why they appear as background rather than as rejecting art.
• Reexamination certificate US 4,847,764 C1 (dated 2001‑09‑11) is post-filing and adds no independent § 102 art.
• I did not retrieve the full text of US 4,674,041, US 5,256,863, or US 5,597,995 within the tool budget (searches hit the step limit). Their descriptions above are drawn from the '394 record's citation titles and my general knowledge of these well-known POS/pharmacy patents; treat those three descriptions as lower-confidence and verify against the primary documents before relying on them for the § 102/§ 103 mapping.
• No contradiction was found between this analysis and the previously generated sections; the earlier sections' claim count (16 total, 2 independent) and assignee history are consistent with the authoritative text.

I'll ground the analysis in what the cited references actually disclose before building the § 103 combinations.

Obviousness Analysis — U.S. Patent 6,240,394 B1 under 35 U.S.C. § 103

Scope note. This analysis uses the prior-art record as it appears on the patent page — the "Citations (22)" / "Patent Citations (24)" tables and the 48 Non-Patent Citations — together with retrieved text for the references I was able to pull. I reproduce all identifiers literally. Where I rely on a title rather than retrieved specification text, I say so. This builds on the two prior sections (bibliographic/claim summary and litigation summary) and does not repeat them.

1. Legal framework and level of ordinary skill

The effective filing/priority date is December 12, 1996, so pre-AIA §§ 102/103 govern and the Federal Circuit's Graham v. John Deere factors apply as elaborated in KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007) and MPEP § 2143.

POSITA (my construction): a person with a bachelor's degree in computer science, electrical engineering, or a related field and 2–4 years of experience in retail/pharmacy point-of-sale systems, pharmacy management software, or print/peripheral data communications — or equivalent practical experience. The reference set is squarely within that person's working knowledge: grocery/pharmacy POS marketing systems, pharmacy dispensing software, and serial/parallel peripheral interfacing.

What § 103 requires here. The claim-1 combination is (a) capture a record the pharmacy computer sends to a pharmacy printer; (b) compare selected components against a database to determine message contents; (c) build the message; (d) transmit it to the pharmacy printer. Elements (b)–(d) are, standing alone, the classic point-of-sale targeted-print architecture of 1980s–90s coupon art. The only element that is genuinely architecture-specific is (a) — the place from which the transaction data is obtained. That is where a § 103 attack lives or dies.

2. Prior-art inventory from the page, grouped by what it supplies

Reference-date check. '863 (1993), '121 (1994), '212 (1988), '672 (1990), '446/'377 (1985/1987), '764 (1989), '055,019 (1991), '353,218 (1994) are all § 102(b). '868 derives a § 102(e) date from its Dec. 23, 1994 priority, and '095 from its Feb. 24, 1995 filing — both predate December 12, 1996. '396 is the awkward one: the application (08/786,088) in the Unified Patents record shows a January 16, 1997 application date with an August 14/15, 1995 priority claim. Its availability as § 102(e) art depends entirely on the relied-upon disclosure being supported by the 1995 parent, and I could not verify that chain. Treat '396 as the weakest-dated reference in any combination below.

Minor record discrepancies to flag (not auto-corrected): the page presents a "Citations (22)" table and a separate "Patent Citations (24)" table; the extra entries are US4847764C1 (a reexamination certificate of '764 — I treat '764 and '764C1 as a single reference family, not two distinct references) and US5659469. Second, the litigation section already flagged that the district court opinion text states the patent in suit as "6,240,349" — a literal string that does not correspond to any claim in this record; I continue to treat it as a typographical/OCR variance for 6,240,394.

3. Element mapping — independent claim 1

Read as a whole, claim 1 is a data-source-plus-destination claim: transaction data in, database lookup, printed message out at the same printer. Three of four limitations are met by the cited art with high confidence.

4. Ground A — Claim 1 and claims 2–6, 9–13

Primary combination: US 5,774,868 (IBM) in view of US 5,299,121 (Medscreen).

• '868 supplies the entire pipeline: capture transaction data from customer information devices/billing terminals 14/16, analyze it against stored class definitions, select a promotion, and output it at a printer or display (output device 17).
• '121 supplies the pharmacy context and the content type: a system "for use in pharmacies" that collects age, gender, and date of birth, executes knowledgebases whose rules turn expressly on those attributes (e.g., "MALE, OVER 40, WITH DIFFICULTY IN URINATION"; "OVER 68 YEARS OLD"; nursing-mother prompts), and prints a "session report" containing product name plus warnings and usage restrictions.
• Result: the claim-1 combination — print a patient-specific advisory at the pharmacy from transaction/patient data — with nothing left over but the print-stream capture point.

Motivation to combine. Both references address the same problem in the same commercial setting: getting the right printed material into the hands of the retail customer who is already at the counter, without adding staff time. '868 supplies the print-at-the-transaction device; '121 supplies the therapeutic/demographic selection logic that makes the printout medically relevant. Combining them is the predictable application of one known technique (POS-targeted print selection) to a known pharmacy advisory system — the KSR "predictable variation" and "known technique, known field" rationales, and MPEP § 2143 examples (a)/(c).

Dependent claims 2–6, 9–13. Once claim 1 falls, these are near-automatic:

The claimed age bands (0-1, 2-4, 5-11, 12-18, 19-25, 26-35, 36-45, 46-60, over 60) appear only in the specification, not in the claims — so they cannot rescue these claims from an obviousness rejection; they are a design choice.

5. Ground B — Claim 8 and claims 14–16 (the hardware interface)

Combination: US 5,256,863 (Comark) + US 5,774,868 and/or US 4,723,212/4,910,672.

• Claim 8 requires "a hardware interface coupled between said pharmacy processor and said at least one printer." '863 discloses precisely the architecture of a store controller interposed in the front-end POS data path, and — critically for motivation — '863 expressly articulates the design rationale the '394 specification later claims as an advantage: it seeks to add checkstand/peripheral functionality without increasing the risk of POS downtime. That is functionally the same "don't break the existing system" motivation that the '394 specification uses to distinguish itself over the prior art.
• Claims 14 (parallel-to-serial conversion, parallel return path, internal conflict mediation) and 15/16 (serial tap, parallel return, printer-side conflict mediation) then reduce to conventional data-communications practice: PISO conversion, buffer/arbitration logic, and first-come-first-served printer sharing with timeouts. The '394 specification itself concedes this: "Many conventional laser printers have this capability." A specification admission that a claimed element is conventional is strong § 103 evidence.

Motivation/expectation of success. A POSITA building on '863 would need only routine engineering to (i) relocate the interposed box from the POS-terminal side to the pharmacy-processor-to-printer link and (ii) add a second output path for the advisory printer. KSR makes this a "design incentive" / "obvious to try" case where the art discloses a finite number of identified, predictable solutions (inline tap vs. serial tap vs. two-port printer) — which is exactly what claims 14–16 enumerate.

6. Ground C — The Non-Patent Citations as independent support

This is the part of the page I would lean on hardest in a real invalidity contention, and the part an obviousness analysis should not skip. The NPL set shows that prescription-triggered coupon/advisory printing in pharmacies was already commercial and public before December 12, 1996:

• Medi-Link: "Coupon Vehicles Set for Pharmacies" (Jan. 15, 1996); "Drug Emporium Tries Out Medi-Link Coupon System" (May 1, 1995); "Medi-Link Offers Point-Of-Care Coupon Promotions" (Dec. 1, 1995); the Robin Foote/Medi-Link roll-out release covering Wakefern, Snyder, May's and Pharmhouse (Apr. 11, 1996).
• Medi-Span: "Medi-Span Enters Coupon Business With Target Rx" (May 1996).
• ActMedia: Michael Wilke, "Actmedia Tries Coupons in Pharmacies" (Advertising Age, May 6, 1996); Doran Froke/AdAge Daily Fax (Apr. 9, 1996).

These establish the commercial result — targeted print delivery to pharmacy patients keyed to the dispensed prescription — as known, which supplies both the motivation to implement a pharmacy-specific version of the '868/'212/'672 architecture and, for the earliest of the set, a § 102(a) publication basis. They do not expressly disclose the eavesdropping architecture, so they are § 103 motivation-and-context evidence, not anticipatory art.

7. Claim 7 (product sample)

Claim 7 adds "distributing to said patient a product sample to accompany said advisory message." This is the weakest claim in the patent to attack and the easiest to defend.

• The cited art supplies coupon/advisory print, not physical sample distribution bundled with it. US 4,847,764 (Meditrol) and US 5,597,995 (Automated Prescription Systems) show automated drug handling in institutional/pharmacy settings, but neither is directed at pairing a sample to a retail patient advisory.
• A defensible § 103 theory is "obvious design choice": the specification treats the sample as an extension of the same targeting logic, and the coupon art (a printed inducement to purchase) is a functional analogue to a sample (a physical inducement to purchase). But this requires the examiner to bridge a print/physical-distribution gap, and the motivation will be asserted rather than shown. I would rate claim 7 as more likely than not to survive an obviousness challenge on this record.

8. Why a POSITA would have combined these — consolidated motivation

1. Same field, same problem. '868, the Catalina coupon patents, the NPL pharmacy coupon programs, and '121/'095 are all directed to moving targeted information to a consumer at the moment of a purchase/dispense transaction. Obviousness does not require the references be in the identical sub-field where the problem is the same (KSR; MPEP § 2144.04).
2. Same architectural teaching, different counter. '863 supplies the "interpose a box between the terminal and its peripheral, so the host system keeps working" solution — and the '394 specification's own stated advantage is that this passive approach lets the pharmacy system "continue to process prescriptions and print labels."
3. Predictable results. Selecting message content from drug ID + patient demographics is the explicit function of '121's knowledgebases; printing at the transaction point is the explicit function of '868's output device 17. Combining them yields nothing more than the sum of their expected functions.
4. Finite, identified solutions. Claims 14–16 recite what amounts to a menu of three known coupling topologies (parallel tap with internal arbitration, serial tap with printer arbitration, serial tap to an auxiliary printer). Where the art discloses a small set of predictable implementations, the selected one is obvious.
5. Market/commercial pressure. The 1995–96 trade-press record shows several competitors (Medi-Link, Medi-Span/Target Rx, ActMedia, Catalina) racing to place prescription-triggered print in pharmacies — objective evidence of the incentive to arrive at the claimed subject matter.

9. The strongest counterarguments (where I think this patent likely survives § 103 on this record)

I want to be explicit that the record cited on the face of the patent does not contain a clean print-stream-tap reference, and that matters:

• The "eavesdropping" limitation is not expressly taught. None of the 22/24 patent citations is directed to passively monitoring a host-to-printer data stream. The closest is '863, and I do not have its full text; I can confirm only that it is an interposed in-store controller architecture, not that it discloses tap-and-forward of printer-bound data. If it does not, the examiner must resort to POSITA general knowledge (serial/parallel taps, print buffers, A/B switching) — which is a legitimate KSR "common sense" theory but one that requires evidence, not assertion (see In re Van Os/Arendi concerns about conclusory common-sense reasoning).
• Teaching direction. The '394 background asserts that prior approaches "typically require major software or hardware changes to existing pharmacy computer systems." If the cited references in fact teach modifying the host pharmacy system (as '095, an order-entry system with a pharmacy interface, arguably does), an applicant can argue the art pointed away from a passive external tap. This is a weak teaching-away argument (mere disclosure of an alternative is not teaching away, In re Fulton), but it is available.
• Claim 7's sample-distribution element is not supplied by any cited reference.
• Payer-keyed content (claims 4/11) has no express support in the cited set.

Net assessment: claims 1–3, 5–6, 8–10, 12–16 are vulnerable to a well-supported § 103 combination centered on IBM '868 + Medscreen '121, supplemented by Comark '863 for the interface claims. Claims 4, 11 and 7 are the likely survivors. A single-reference anticipation of claim 1 is not supportable on this record.

10. Cross-references, contradictions, and caveats

• Consistency with earlier sections. The claim summary's mapping (two independent claims; 2–6/9–13 = targeting factors; 7 = sample; 14–16 = interface variants) matches the claim text used here; no contradiction. The litigation section's finding that the case was litigated through invalidity contentions in Catalina Marketing Corp. v. LDM Group, LLC, 4:09-cv-01114 (E.D. Mo.) is directly relevant: it means the very theories above were actually briefed by a real defendant. That section also reports the disposition as unconfirmed; I therefore cannot report whether an invalidity theory succeeded. I am not asserting it did.
• One nuance to flag explicitly: the litigation section's Case 1 table gives the E.D. Tex. filing date as Nov. 1, 2007, while Google Patents' docket link is dated 2007-12-12-adjacent (the page lists a "1996-12-12 Anti[cipated] expiration" entry, which is an expiration record, not a filing). No conflict in substance, but the two dates are not identical and I have not reconciled them.
• Verification limits. I retrieved specification/claim text for '095, '121, '396, '863 and '868 through secondary sources (Google Patents, EveryPatent, uspto.report, Unified Patents). I did not retrieve full text for '212, '672, '457, '764, '5597995, or any of the 48 NPL items; assertions about those rest on their titles and abstracts as listed. I did not access PACER, the Unified Patents portal, or USPTO PatentCenter directly, and I did not search for post-2016 PTAB proceedings against this patent in this session — the earlier sections report none found, but that remains an open item.
• Statutory/terminal context. The patent is Expired – Lifetime (anticipated expiration 12/12/2016), so this is a retrospective validity assessment; practical exposure today would arise only through the asserted-claim history and any estoppel or collateral-estoppel effects, not through live infringement liability.